Home
Solutions
Products
Pricing
Resources
Request Demo
Start Free
Menu Search Account

LegiStorm

Get LegiStorm App Visit Product Demo Website
» Get LegiStorm App
» Get LegiStorm Pro Free Demo
StateStorm

Weekly Updates

LegiStorm is constantly adding new information on the people, places and reports in our database. In the past week, LegiStorm added:

  • 376 new people
  • 171 new organizations
  • 408 new photos
  • 1234 job history records for people in our database
  • 653 education records for people in our database
  • 1467 contact addresses, emails and URLs (LinkedIn, Facebook, etc.)
  • 3 new people through the revolving door
  • 109 new policy reports
  • 43 new trips to our privately funded travel database
  • 629 new personal financial disclosures
  • 15148 new press releases
  • 11 new town halls
  • 25 new hearings

Caught Our Eye Rss

» More from Caught Our Eye
» More from our DevBlog

Prescription Drugs: Prices and Regulation in Canada and Europe

  Premium   Download PDF Now (12 pages)
Report Type Reports and Testimonies
Report Date July 27, 1994
Report No. T-HEHS-94-213
Subject
Summary:

GAO compared U.S. prescription drug prices with the prices of identical drugs in Canada and the United Kingdom. GAO also reviewed the policies that Canada, France, Germany, Sweden, and the United Kingdom have adopted to limit national expenditures on prescription drugs. Although government regulation has restrained drug prices in these five countries, the implications--and the desirability--of similar intervention in the U.S. pharmaceutical market are unclear. More specifically, the effects of a price reduction in any of these countries may differ from the effects of a similar price cut in the United States because each of the five countries represents a relatively smaller share of the global pharmaceutical market. In addition, the particular price and spending control policies used in these countries may not be readily transferred to the United States because of institutional differences across countries. In any case, any gains from regulation of drug prices or spending must be weighed against the consequences of such regulations for pharmaceutical research and development.

« Return to search Government Accountability Office reports

HomeAbout Us Contact UsPrivacy PolicyTerms of UseJoin Us
© LegiStorm
LegiStorm
2101 L St. NW, Suite 300
Washington, DC 20037
(202) 360-4172 / congress@legistorm.com